The aims of the present study are to investigate sub-cellular location, differential expression in different cancer stages and functional role of FAM134B in colon cancer development. FAM134B expression was studied and quantified at protein and mRNA levels in cell lines using immunocytochemistry, Western blot and real-time PCR. In vitro functional assays and an in vivo xenotransplantation mouse models were used to investigate the molecular role of FAM134B in cancer cell biology in response to FAM134B silencing with shRNA lentiviral particles. FAM134B protein was noted in both cytoplasm and nuclei of cancer cells. In cancer cells derived from stage IV colon cancer, FAM134B expression was remarkably reduced when compared to non-cancer colon cells and cancer cells derived from stage II colon cancer. FAM134B knockdown significantly (P < 0.05) increased the proliferation of colon cancer cells following lentiviral transfection. Furthermore, FAM134B suppression significantly increased (34-52%; P < 0.05) the clonogenic capacity, wound healing potential of and increases the proportion of cells performing DNA synthesis (P < 0.01). Xenotransplantation model showed that larger and higher-grade tumors were formed in mice receiving FAM134B knockdown cells. To conclude, expression analysis, in vitro and in vivo indicated that FAM134B acts as a cancer suppressor gene in colon cancer.
INTRODUCTION
FAM 134B (Family with sequence similarity 134, member B), also called JK1, is located at chromosome 5p15.1, downstream of d-catenin. Our group first reported the importance of this gene in human disease [1] . FAM 134B was noted to play important roles in the pathogenesis of oesophageal squamous cell carcinoma [1] . This gene encodes a cis-golgi transmembrane protein, which is essential for the long-term survival of nociceptive and autonomic ganglion neurons [2] . Hereditary sensory and autonomic neuropathy type IIB is associated with the mutations of FAM134B [3, 4] . In addition, this gene may have a role in susceptibility to vascular dementia [5] . Also, over expression of FAM134B mRNA was associated in patients with increased risk of allergic rhinitis [6] . Scheubert et al. noted that FAM134B acts as a biomarker for pluripotency of stem cells in mice. The finding was based on the genetic algorithm and bioinformatics on multiple Gene Expression Omnibus (GEO) data sets [7] . A recent study noted that FAM134B regulated endoplasmic reticulum turnover by selective autophagy [8] .
In colorectal cancer, we have found that FAM134B is a growth-related gene, which has a significant role in cancer pathogenesis by exhibiting the properties of a tumor suppressor gene [9] [10] [11] . In a large cohort of patients with colorectal cancer tissues samples, FAM134B mRNA expression and DNA copy number were noted to be significantly lower in colorectal cancer when compared to non-cancer colon tissues or pre-invasive colorectal lesions (colorectal adenomas) [9] [10] [11] . In addition, a functional study by our team demonstrated that FAM134B inhibits the invasion and migration of colon cancer in vitro [10] . The results of these studies imply that FAM134B is involved with different biological networks in colorectal cancer pathogenesis. Despite its clinical and pathological significance, FAM134B's tumor suppressor properties and its impact in cancer cell biology has not been studied in depth. In addition, the stage dependant expression and localization of FAM134B in cancer cells are still unclear. In this study, we aim to examine the cellular distribution, expression profiling, and downstream effects of FAM134B suppression on cell lines derived from different pathological stages of colon cancer both in vitro and in vivo.
MATERIALS AND METHODS

Cell Culture
Three colon cancer cell lines and one non-cancer colon epithelial cell line were used in this study. The colon cancer cell lines included SW-480 (ATCC CCL228; Duke's class B/stage II, colonic adenocarcinoma), SW-48 (ATCC CCL-231; Duke's class C/stage III colonic adenocarcinoma) and HCT116 (ATCC CCL-247; Duke's class D/stage IV colonic carcinoma) [12] [13] [14] [15] . The non-neoplastic colon epithelial cell line used was FHC (ATCC CRL-1831). All the cell lines were maintained according to ATCC guidelines. Colon cancer cell lines (SW-480 and SW-48) were maintained in Leibovitz's L-15 medium containing 10% fetal bovine serum (FBS) and 1% penicillin/ streptomycin at 378C in a CO 2 incubator. HCT116 cells were cultured in McCoy's 5a medium modified with 10% FBS and 1% penicillin/streptomycin at 378C in a CO 2 incubator. The cells in FHC were cultured in Dulbecco's Modified Eagle Medium (DMEM): F-12 medium supplemented with 10 ng/ ml cholera toxin, 0.005 mg/ml insulin, 100 ng/ml hydrocortisone, 0.005 mg/ml transferrin, and 10% FBS 378C in a CO 2 incubator.
Immunocytochemistry
Immunocytochemistry was performed to identify the cellular localization of FAM134B protein in the recruited cell lines. The cells were fixed with 70% icecold ethanol for 10 min and were permeabilised with 0.1% Triton X-100 for 5 min. Following protein block with 5% BSA (bovine serum albumin), cells were incubated with anti-rabbit FAM134B antibody (Santa Cruz, Dallas, TX) for overnight at 48C. They were incubated with secondary antibody (1:1000; antirabbit IgG-poly-horseradish peroxidase) in 5% BSA for one hour at 378C. A brown positive staining was obtained by developing the peroxidase activity with freshly prepared 3, 3 0 -diaminobenzidine (DAB) and substrate chromogen solution (Leica, North Ryde, NSW, Australia). After washing with phosphate buffered saline (PBS), cells were visualized under light microscopy (Olympus CKX41, Macquarie Park, NSW, Australia). Each staining was run in triplicate on a 24 well plate.
Immunofluorescence
To confirm the cellular localization of FAM134B protein in different cell lines (SW-480, SW-48, HCT116, and FHC) immunofluorescence analysis was performed. The cells were seeded on cover slips at a density of $10,000/cm 2 and were incubated at 378C for 12 h. Then, after being washed with PBS, cells were fixed with freshly prepared fixative (70% cold ethanol), for 30 min and were permeabilized with 0.1% Triton X-100 for 5 min. Afterwards, cells were blocked with 5% BSA for 1 h at room temperature. Cells were then washed with PBS and were incubated with anti-rabbit FAM134B (Santa Cruz) (1:150) and anti-goat giantin, a cis-golgi marker protein antibody (Santa Cruz) (1:150) at 48C overnight. This was followed by 2 h of incubation with secondary antibody labelled with fluorescein isothiocyanate (FITC) and Texas red fluorophore (Sigma-Aldrich, St Louis, MO) at room temperature and was later mounted on glass slides, sealed with nail polish, and then observed under a confocal microscope (Nikon A1Rþ, Nikon Inc., Tokyo, Japan).
Quantitative Real Time PCR (qPCR) Analysis
For quantitative PCR, total RNA was extracted from cell lines using miRNeasy mini kits (Qiagen, Valencia, CA). First-strand cDNA was then generated using DyNAmo TM cDNA Synthesis Kits (Qiagen) as previously described [16] . FAM134B mRNA expressions change in cell lines were examined using IQ5 multicolour real-time PCR detection system (Bio-Rad, Hercules, CA). qPCR was performed in a total volume of 20 ml reaction mixture containing 10 ml of DyNAmo Flash SYBR green master mix (Bio-Rad), 1.5 ml of each 5 mmol/L primer, 3 ml of cDNA at 50 ng/ml, and 4 ml of 0.1% diethylpyrocarbonate (DEPC) treated water as previously described [17] . The amplification efficiencies were normalized to that of the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Primers that were used in this study are given in supplementary data 1.
Western Blot Analysis
Total proteins were extracted from cultured cells with lysis buffer (Bio-Rad, Gladesville, NSW, Australia) and subsequently were quantitated by absorbance spectrometry [10] . Afterwards, total protein (30 mg) was separated by 15% SDS-PAGE (BioRad) and transferred to nitrocellulose membranes (Bio-Rad). The membrane was blocked with 5% nonfat milk powder for 2 h at room temperature. Then incubated with anti-rabbit FAM134B polyclonal antibody (Santa Cruz) at 1:150 and polyclonal GAPDH antibody (Santa Cruz) (1:2000) overnight at 48C. Membranes were then washed three times with PBS-T and incubated with the rabbit secondary antibody (Santa Cruz) (1:5000) at room temperature for 2 h. Protein bands were developed and detected with a chemiluminscence HRP detection kit (Bio-Rad). Images were taken with the ChemiDoc MP Imaging system (Bio-rad). Expression of FAM134B protein was quantified and normalized to GAPDH with ImageJ 1.48 software [18] .
FAM134B shRNA Transfection
FAM134B gene knockdown in colon cancer cells (SW-480 and SW-48) was performed using transduction ready lenti-viral particles (shRNA) and a transfection reagent, polybrene (Santa Cruz). Two independent shRNA lentiviral particles from Santa Cruz (shRNA 1; sc-108551-v) and Sigma-Aldrich (shRNA 2; MISSION shRNA; TRCN0000176408) were used in this study, which contained three target-specific constructs that encode 19-25 nucleotide (hairpin) shRNA designed to knock down FAM134B gene expression. Control cells were prepared using a non-targeted scrambled control shRNA (Santa Cruz). Following transfection, cells were treated with puromycin (7.5 mg/ml) and selection of stable clones expressing FAM134B shRNA and control shRNA were carried out as previously described [10] . Post transfected reductions of FAM134B mRNA and protein expression were analyzed using qPCR and Western blot, respectively. A GMO (genetically modified organism) project approval was obtained from Griffith University Institutional Biosafety Committee (NLRD/006/15). The experiments were carried out in accordance with the approval guide lines.
Cell Proliferation Assay
A cell proliferation assay using a cell counting kit-8 (Sigma-Aldrich) was performed to observe the changes of proliferation in FAM134B knockdown cells. Both SW-480 and SW-48 cells were first seeded in flat-bottom 96-well plates at 1 Â 10 4 cells/well. Cell proliferation was determined on days 1-5 after the initial seeding with CCK-8 (cell counting kit-8) following manufacturer instructions.
Wound Healing Assay
A wound healing assay was performed to determine the effect of FAM134B knockdown on the capacity of cells to migrate. FAM134B shRNA treated cells, wild type (non-transfected) and control cells were cultured in appropriate medium until 80-90% confluence as a monolayer. Then scratches were made with a 200 ml pipette tip across the centre of culture plates. Fresh media was then replaced and incubated for 5 d of investigation. Images were taken to monitor the changes among the cells type on day 1-5. Wound areas on different days of all cell types were measured and compared with ImageJ 1.48 software [18] .
Colony Formation Assay
Approximately 250 cells were seeded in 6-well plates with 2 ml of complete medium. The cells were then cultured at 378C in 5% CO 2 and saturation humidity. After 16 d, when microscopic clones were noted in the plate, growing of the cells was stopped. At that point, the media was discarded and cells washed with PBS. Then, the cells were fixed with 70% cold ethanol for 15 min. Afterwards, the clones were stained with crystal violet (0.5%) for 2 h at room temperature. Finally, after being air-dried, images were taken from the plates and clone formation rates were calculated.
Apoptosis Assay
FAM134B related apoptotic changes following knockdown in the colon cancer cells was assayed by using nuclear stain, Hoechest 33342 and DAPI (4 0 ,6-diamidino-2-phenylindole). In short, cells were fixed in 4% paraformaldehyde for 10 min and permeabilised with 0.1% Triton-X-100 for 5 min at room temperature. After washing with PBS, the cells were stained with Hoechest 33342 (10 mg/ml) and DAPI (50 mg/ml) for 30 min at 378C. Finally, the cells were observed under fluorescence microscope (Olympus) and percentages of apoptotic cells recorded in three independent experiments from different plates.
Apoptosis assays on FAM134B shRNA transfected, control shRNA treated, and wild type cells were also performed using an annexin V-FITC apoptosis detection kit (Invitrogen, Carlsbad, CA). The numbers of annexin V and propidium-iodide positive cells were detected using BDFACS Calibur (BD Biosciences, Franklin Lakes, NJ) and data were processed with FlowJo v10 software (FlowJo LLC, Ashland, OR).
Cell Cycle Analysis
FAM134B knockdown and control/non-transfected wild type cells were fixed with cold 70% ethanol for one hour as previously described [19] . After washing with cold PBS, 5 ml of RNase A (10 mg/ml) was added to the cells and incubated for one hour at 378C. Finally, 10 ml of propidium iodide solution (1 mg/ml) was added to the cell suspension and analysis was performed with flow cytometry (BD FACSCalibur, BD Biosciences).
In Vivo Mouse Model
Four groups (n ¼ 6 in each group) of severe combined immunodeficiency (SCID) mice (3-wk-old males) were used for this study. Animal ethics approval for this study was obtained from the University Animal Ethics Committee (Approval number: 45005204-10-0) and the study was carried out in accordance with the approval guidelines.
Mice in group I and group II received SW-480 and SW-48 FAM134B knockdown cells, respectively, whereas group III and group IV mice received SW-480 and SW-48 control cells, respectively. Approximately 1 Â 10 6 cancer cells were injected subcutaneously into the flanks of the mice using a 1 ml syringe. After 21 d of cancer cell implantation, the mice from all groups were sacrificed using standard operation procedures [20] . The weight and size of the tumors noted in the mice were recorded according to published protocol [20] . The tumors were collected, fixed in 10% formalin and embedded in paraffin [20] . Histopathological examinations of the specimen were performed after haematoxylin and eosin staining of the sections taken from the paraffin blocks. The grade and differentiation of tumors from the blocks were analyzed.
RESULTS
Localization of FAM134B in Colon Cancer
Both cytoplasmic and nuclear localization of FAM134B protein was observed with a predominant cytoplasmic expression in colon cancer cells ( Figure 1A and supplementary data 2A) . FAM134B protein co-localized with cis-golgi marker protein giantin in studied colon cancer cells ( Figure 1A ). Immunocytochemistry analyses also revealed cytoplasmic and nuclear expression of FAM134B protein in all cell lines (supplementary data 2B). Also, the expression level of FAM134B protein was noted to be reduced (weak signal) in colon cancer cell line derived from stage III colon cancer (SW-48) when compared to a cancer cell line derived from stage II colon cancer (SW-480) and normal colon cell line (FHC) ( Figure 1A and B and supplementary data 3).
FAM134B mRNA and Protein Expression Is Stage Dependent in Colon Cancers
Expression levels of FAM134B at both mRNA and protein levels showed significant changes in the three colon cancer cell lines derived from cancers of different pathological stages when compared with normal colon epithelial cells after normalizing with housekeeping gene GAPDH. With the advancement of cancer stages, FAM134B mRNA expression was found to be markedly reduced. Cancer cells derived from stage III or stage IV colon cancers (SW48 and HCT116) showed significant lower FAM134B expression in comparison to those from stage II colon cancer (SW480) and non-neoplastic colon epithelial cells ( Figure 1C and D) . The inverse ratio of FAM134B mRNA expression in FHC and SW-480 cell were 2.125 AE 0.24 and 1.952 AE 0.53, respectively whereas the inverse ratio in HCT116 was 0.524 AE 0.07 ( Figure 1C ). The fold change of FAM134B mRNA expression also showed similar fashion ( Figure 1D ). In concordance to the mRNA expression, FAM134B protein ($54 kDa) expression also showed significant reduction in more advanced colon cancer cell lines (HCT116, SW-48 versus SW480/FHC) ( Figure 1E and F). The relative protein band intensity of FAM134B expressions in FHC and SW-480 were 0.93 AE 0.1 and 0.63 AE 0.3, respectively. On the other hand, the intensity of FAM134B protein expressions were 0.2 AE 0.4 and 0.11 AE 0.02 in SW-48 and HCT116 cells, respectively ( Figure 1F ).
Knockdown of FAM134B Gene
FAM134B mRNA levels in cells treated with both shRNA (shRNA 1 and shRNA 2) showed $a fourfold suppression of FAM134B in both SW-480 and SW-48 cell lines when compared to non-transfected and control shRNA treated cells (Figure 2A and B) . Also, cells treated with FAM134B shRNA (shRNA 1 and 2) showed significant reduction of FAM134B protein levels when compared to the control and nontransfected wild type cells ( Figure 2C-E) . As shRNA 1 exhibited higher knockdown efficiency, in subsequent experiments the stable cells generated from the treatment of shRNA 1 was used. The comparison of FAM134B expression in shRNA treated, scrambled control, and wild type cells were also noted (supplementary data 4).
Tumor Suppressor Properties of FAM134B In Vitro
Colon cancer cells treated with FAM134B shRNA showed increased cell proliferation when compared to control and non-transfected cells (wild type counterparts). The increased proliferation of cells was observed in all 5 d of the experiment with a similar trend in each cell line ( Figure 3A and B). In addition, FAM134B shRNA treated colon cancer cells showed remarkably increased colony formation properties in comparison to the control and non-transfected wild type colon cancer cells ( Figure 3C-F and supplementary data 5) . Similarly, FAM134B shRNA treated cells had a higher cell migration potential than the control and wild type cells as they healed the created wound faster when compared to their counterpart (Figure 4 ). FAM134B suppressed cancer cells healed the wound completely on 4th d of initial scratch whereas non-treated and control cells took more time to heal the wounds.
Apoptotic Changes
There was no statistically significant difference of apoptotic cell populations noted among the different cells groups (FAM134B shRNA treated, scrambled control, and wild type non-transfected cells). Flow cytometric analysis showed a slight decrease (2-4%) of apoptotic cells in FAM134B shRNA treated colon cancer cells (Figure 5A and D) . Also, there was no notable change observed with nuclear staining among the FAM134B shRNA and control cells groups (Supplementary data 6 and 7).
Alteration of Cell Cycle Kinetics
Cell cycle analysis revealed an accumulation of cells in the S phase of the cycle in FAM134B suppressed cells when compared to control and non-transfected wild type cells. In case of control SW-480 cells, the percentage of S phase cells was 30.9 AE 4.5%, while in FAM134B knockdown SW-480 cells, the S phase population increased remarkably to 43.0 AE 4.13% (P < 0.01) ( Figure 5E and F) . Similarly, in FAM134B shRNA treated SW-48 cells, the proportion of S phase cell was significantly (P ¼ 0.008) increased (32.1% vs. 43.1 AE 3.1%) when compared to that of control cells ( Figure 5G and H) . These increments were parallel with a decreased in cell population in the G2/M phase. These results indicated that regulation of the synthesis phase of the cell cycle could be altered by the suppression of FAM134B.
In-Vivo Confirmation of FAM134B Tumor Suppressor Properties
The functional role of FAM134B in colon cancer pathogenesis was investigated in vivo by subcutaneously injecting FAM134B knockdown and control cells into SCID mice. Local tumors were formed in all experimental animals (24/24) , respectively) treated mice ( Figure 6A ). The weights of tumors from FAM134B downregulation cells treated mice were higher when compared to that of control groups ( Figure 6B ). In mice receiving FAM134B suppressive cells (SW-48 and SW-480) the tumors weight were 0.2 AE 0.08 and 0.315 AE 0.07 gram whereas in control groups the weight were 0.113 AE 0.05 and 0.124 AE 0.04 gram, respectively ( Figure 6B ). Pathological examination of the tumors confirmed that the tumors produced in mice were adenocarcinomas, the tumor type that was expected ( Figure 6C-F) . In addition, mice treated with FAM134B knockdown SW-48 colon cancer cells produced a high grade (poorly differentiated) carcinoma when compared to control cells ( Figure 6E and F) .
DISCUSSION
The results of this study indicate that FAM134B plays a direct role in cancer pathogenesis through regulation of cellular proliferation and mobility, operating as a tumor suppressor.
As the first of its sub-studies, this research investigated the physical localization of FAM134B protein in cell lines of different colon cancer stages. Immunostaining of colon cancer cells revealed a cytoplasmic and nuclear distribution of the protein with predominantly cytoplasmic expression (Figure 1) . A previous study by our team also noted nuclear localization of FAM134B protein in colorectal carcinoma, adenoma, and non-tumor mucosa [11] . FAM134B was noted to co-localize with the cis-golgi matrix protein giantin in the cell lines tested in our research. Kurth et al. previously demonstrated that FAM134B is a cytosolic (cis-golgi matrix) protein in N2a cells, a tumor cell line that is associated with autonomic ganglion neurons [2] . Another study by Khaminets et al. reported that FAM134B protein co-localized with endoplasmic reticulum marker proteins (KDEL, CLIMP, and SEC61B) in A549, HeLa, and U20S cells [8] . These results, along with our own observation of nuclear staining for FAM134B support the potential for the protein to have multiple localizations in the cell.
The translocation of FAM134B protein to the nucleus in cancer tissues observed in our previous study and this research indicates the possibility of nucleus-cytoplasmic translocation of FAM134B protein in a certain subset of colorectal cancers, for reasons yet unknown. The tumor microenvironment, especially hypoxia may induce the translocation of this novel protein, or it may be a specific response by cells of colorectal origin, given the lack of other observations of nuclear localization in other studies. This kind of translocation of proteins in cancer is not a rare event, however, and it can have direct or indirect effects on the function of other genes. The precise mechanism of the function of FAM134B in cancer cells is unknown. It is possible that translocation to the nucleus or to the endoplasmic reticulum allows new interactions with growth signaling pathways in developing cancer. For example, both nuclear and cytoplasmic localizations of BARD1 have been observed and increased cytoplasmic localization of BARD1 protein was associated with apoptosis [21] . A similar mechanism may be attributed to FAM134B cytoplasmic localization in human cancers. Alternatively, translocation of FAM134B away from its normal location may sequester it from its usual binding partners and prevent its normal activity.
Without knowing the precise functional partners of FAM134B, it is difficult to know whether it has a single function in normal tissues, or whether the protein has alternative effects in some tissue types, differentiation stages, or developmental programs. It is possible that nuclear localization of FAM134B is normal in undifferentiated cells. In cancer, this may represent the kind of reversion to stem-like characteristics seen for other mechanisms. Thus, further investigation with in-depth in-vitro and in-vivo analyses should be used to study the detailed mechanisms of this translocation in both normal and malignant cells and its functional consequences.
One of the other results shown in this study on FAM134B and our previous work on the gene is that its expression seems to be stage dependent. In human colorectal adenocarcinoma, eukaryotic translation initiation factor 4E (eIF4E) has showed stage dependent expression [22] . In the early stage of colorectal cancer, eIF4E protein is expressed significantly higher than in late stage cancers [22] . The reduced expression of FAM134B protein in advanced stage colorectal cancer when compared to early stage in this and our earlier study implies that the protein is involved in the molecular pathways of colorectal cancer pathogenesis, and it might act as a tumor suppressor in colon cancer development. In our previous study, patients with colorectal adenoma (pre-invasive lesion) expressed a higher amount of FAM134B protein and mRNA than non-cancer tissues [11] . On the other hand, lower expression of FAM134B protein and mRNA were noted in advanced stages colorectal cancers [11] . The high expression (protein and mRNA) level of FAM134B in colorectal adenomas, combined with later changes in malignant tissues, suggests that FAM134B plays an important role in cancer initiation and progression. The low expression levels of FAM134B in advanced colorectal adenocarcinomas, combined with results from the The in vitro analyses of this study demonstrated that FAM134B protein and mRNA expression was down regulated in cell lines derived from advanced tumor stages. The most advanced colon cancer cell line used in this research, derived from stage IV colon cancer (HCT116), showed the lowest FAM134B expression (both protein and mRNA level) when compared to the colon cancer cell line derived from stage II colon cancer (SW-480) and the non-neoplastic colon epithelial cell line (FHC). This stage dependent expression of FAM134B further reinforced our hypothesis that FAM134B would act as a tumor suppressor gene in colon cancer pathogenesis and as a prognostic maker in colon cancer.
The molecular causes of the expression reduction of this novel gene both at the mRNA and protein levels in colon cancer are not clear, however. In part, this is due to our lack of knowledge of the how the gene is being regulated and what its function is. Several mechanisms may explain the loss. Mutation (deletion or point mutation) in the gene could be the possible cause of reduced expression, something common for tumor suppressors, but other mechanisms such as gene methylation may also be involved. Additionally, the loss may be caused by different mechanisms in different colorectal cancer subtypes, depending on specific predilections. For example, the hypermethylator phenotype may tend to deactivation of FAM134B via methylation. As this is the first comparative study of FAM134B expression in different cancer cell lines and normal epithelial cell lines, further studies are necessary to confirm exactly how FAM134B expression is altered in cancer progression. These findings of changes in FAM134B expression noted in cancer cell lines were similar to the results obtained from colorectal cancer tissues. This further strengthens the hypothesis that FAM134B possesses tumor suppressor properties in pathologically advanced colorectal cancer cells, both in solid tumors and viable cancer cells. Additionally, the fact that the trend from cancer tissues is repeated in several colorectal cancer cell lines indicates that FAM134B alteration may be a central event in the pathology of many colorectal cancers.
Functional assays with FAM134B suppressed colon cancer cells used in this study further support the tumor inhibitory properties of FAM134B in a colon cancer model. Compared to control shRNA treated and non-transfected wild type colon cancer cells, FAM134B shRNA treated cells showed increased cell proliferation, increased colony formation, and higher migration and wound healing capacity in this study. A previous study from our group also noted that higher FAM134B expression reduced migration and invasion of colon cancer cells [10] . Although the statistical test was not significant, FAM134B knockdown also decreased the apoptotic rate of cancer cells from stages II and IV colon cancers (SW-480 and SW-48) in comparison to that of control and un-transfected cells. The difference of apoptosis observed was approximately a 50% reduction, and from 5% to 2% for SW480 cells and 6% to 3% for SW48 cells ( Figure 5 ). The relatively high error rates in these apoptosis measures may have prevented the accurate detection of this reduced apoptosis. Further experiments using cell lines with higher resting apoptosis rates, or following challenge with apoptosis triggers may determine whether the trend for decreased apoptosis seen in this study is experimental error, a direct suppression of apoptotic pathways or a manifestation of the increased proliferation observed following FAM134B knockdown.
A study from our group noted that knockdown of FAM134B expression increased the migration and invasion capacity of colon cancer cells [10] . These observations strongly suggest that FAM134B negatively regulates colon cancer growth. In contrast to these results, Tang et al. reported that FAM134B promotes cancer cell proliferation and tumor growth in a model derived from oesophageal squamous cell carcinoma [1] . It is worth nothing that other cancer related genes such as cell surface mucin gene family members 11, 12, and 13 (MUC 11, MUC 12, and MUC 13) are also expressed in different ways in colorectal and oesophageal cancers [23, 24] . Lower mRNA expressions of MUC 11, MUC 12, and MUC 13 were noted in colon cancer whereas higher mRNA expressions of these genes were found in oesophageal cancer [23, 24] . Thus, FAM134B may act as both oncogene and tumor suppressor gene in human cancer. The function of FAM134B could depend on the genes that it interacts with in a given cell, which may also be an explanation for altered localization of FAM134B as previously discussed. Researches to examine the mechanism of FAM134B action and identify its binding partners to more completely understand the significance of its expression in different cancer types.
Gene manipulation can modulate and interfere with cell cycle progression. In this study, alteration of cell cycle kinetics following downregulation of FAM134B using shRNA lentiviral particles was investigated. It was noted that FAM134B knockdown caused accumulation of cells in S phase of the cycle. This result indicated that FAM134B might be involved in the regulation of DNA synthesis and down regulation of FAM134B, triggered DNA synthesis via modulating molecules associated cell cycle progression. Such triggering is most likely through the loss of FAM134B suppression of the activity of another protein, causing the G1/S phase checkpoint to be opened. It has been reported, for example, that megakaryoblastic leukemia 1 (MKL1) downregulation causes S phase arrest of the cell cycle via modulating p21 activity, FAM134B may have similar effects, perhaps via interaction with golgi proteins to promote stability or delivery of protein complexes that restrict DNA synthesis, enable ongoing protein production to prepare for DNA replication later on [25] . Further studies to explore the mechanism by which the FAM134B gene causes alterations in the cell cycle kinetics are needed.
Results from our xenotransplantation animal model and previous studies provide further demonstration of the functional role of FAM134B in colon cancer pathogenesis [9, 10] . Tumor weight and size in mice from the FAM134B suppressive group were much higher than that of the control group for both cell lines. Higher-grade tumor formation in mice receiving FAM134B knockdown cancer cells further implied a tumor inhibitory role of FAM134B, and potentially a role in development of other advanced cancer phenotypes. Results from the in vivo study thus validate and translate our in vitro studies. These correlations of in vitro and in vivo findings confirm the tumor suppressive function of FAM134B in colon cancer.
Our previous studies have demonstrated the stage dependent expression patterns of FAM134B in colorectal cancer tissues at mRNA and protein levels [9, 11] . This study confirmed the presence of cytoplasmic and nuclear localization of the FAM134B protein in colon cancer cell lines from different stages. Expression of FAM134B mRNA and protein showed significant changes in cells derived from different pathological stages of colon cancer, matching previous data from human tumor tissues. Knockdown of FAM134B also results in similarly advanced cancer behavior, including increased proliferation, wound healing, colony formation, higher grade tumors, and altered cell cycle kinetics. The differential expression of FAM134B may act as potential prognostic marker in colon cancer pathogenesis. Reduced expression in more advanced colon cancers indicate that it acts as a tumor suppressor in colon cancer pathogenesis. This is confirmed by the results of our in vivo and in vitro studies in colon cancer. It is also possible that FAM134B loss is a central driver of progression in many colorectal cancers, and the protein or gene may be a potential treatment target. New research to identify the mechanism of action of FAM134B in control of cellular growth is needed to fully unravel the role of this gene and enable its effective use in clinical contexts.
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